Idioma:

Exploitation of CD133 for the Targeted Imaging of Lethal Prostate Cancer

Glumac, Paige M ; Gallant, Joseph P ; Shapovalova, Mariya ; Li, Yingming ; Murugan, Paari ; Gupta, Shilpa ; Coleman, Ilsa M ; Nelson, Peter S ; Dehm, Scott M ; LeBeau, Aaron M

Clinical cancer research, 2020-03, Vol.26 (5), p.1054-1064 [Periódico revisado por pares]

United States

Texto completo disponível

Citações Citado por

Enviar para

Título:
Exploitation of CD133 for the Targeted Imaging of Lethal Prostate Cancer
Autor: Glumac, Paige M ; Gallant, Joseph P ; Shapovalova, Mariya ; Li, Yingming ; Murugan, Paari ; Gupta, Shilpa ; Coleman, Ilsa M ; Nelson, Peter S ; Dehm, Scott M ; LeBeau, Aaron M
Assuntos: AC133 Antigen - antagonists & inhibitors ; AC133 Antigen - immunology ; AC133 Antigen - metabolism ; Animals ; Antibodies, Monoclonal - pharmacology ; Biomarkers, Tumor - immunology ; Biomarkers, Tumor - metabolism ; Cell Line, Tumor ; Humans ; Male ; Mice ; Mice, Nude ; Molecular Imaging - methods ; Positron-Emission Tomography - methods ; Prostatic Neoplasms - diagnostic imaging ; Prostatic Neoplasms - drug therapy ; Prostatic Neoplasms - metabolism ; Prostatic Neoplasms - pathology ; Radioisotopes - pharmacokinetics ; Radiopharmaceuticals - pharmacokinetics ; Receptors, Androgen - metabolism ; Tissue Distribution ; Tumor Cells, Cultured ; Xenograft Model Antitumor Assays ; Zirconium - pharmacokinetics
É parte de: Clinical cancer research, 2020-03, Vol.26 (5), p.1054-1064
Descrição: Aggressive variant prostate cancer (AVPC) is a nonandrogen receptor-driven form of disease that arises in men in whom standard-of-care therapies have failed. Therapeutic options for AVPC are limited, and the development of novel therapeutics is significantly hindered by the inability to accurately quantify patient response to therapy by imaging. Imaging modalities that accurately and sensitively detect the bone and visceral metastases associated with AVPC do not exist. This study investigated the transmembrane protein CD133 as a targetable cell surface antigen in AVPC. We evaluated the expression of CD133 by microarray and IHC analysis. The imaging potential of the CD133-targeted IgG (HA10 IgG) was evaluated in preclinical prostate cancer models using two different imaging modalities: near-infrared and PET imaging. Evaluation of the patient data demonstrated that CD133 is overexpressed in a specific phenotype of AVPC that is androgen receptor indifferent and neuroendocrine differentiated. In addition, HA10 IgG was selective for CD133-expressing tumors in all preclinical imaging studies. PET imaging with [ Zr]Zr-HA10 IgG revealed a mean %ID/g of 24.30 ± 3.19 in CD133-positive metastatic lesions as compared with 11.82 ± 0.57 in CD133-negative lesions after 72 hours ( = 0.0069). biodistribution showed similar trends as signals were increased by nearly 3-fold in CD133-positive tumors ( < 0.0001). To our knowledge, this is the first study to define CD133 as a targetable marker of AVPC. Similarly, we have developed a novel imaging agent, which is selective for CD133-expressing tumors, resulting in a noninvasive PET imaging approach to more effectively detect and monitor AVPC.
Editor: United States
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Exploitation of CD133 for the Targeted Imaging of Lethal Prostate Cancer

Glumac, Paige M ; Gallant, Joseph P ; Shapovalova, Mariya ; Li, Yingming ; Murugan, Paari ; Gupta, Shilpa ; Coleman, Ilsa M ; Nelson, Peter S ; Dehm, Scott M ; LeBeau, Aaron M

United States

Buscando em bases de dados remotas. Favor aguardar.